Replaces Prod. #: ALX-340-015
- Potent TP agonist
- Used in cardiovascular studies
- highly cited
U-46619 is a Prostaglandin H2/thromboxane A2 analog and a potent thromboxane A2 receptor (TP) agonist (EC50 = 0.035µM). U-46619 induces platelet shape change and aggregation at 32nM. U-46619 also activates p38 MAPK.
Product Details
| Alternative Name: | 9,11-Dideoxy-9α,11α-methanoepoxy prostaglandin F2α, 9,11-Dideoxy-9α,11α-methanoepoxy prosta5Z,13E-dien-1-oic acid |
| |
| Formula: | C21H34O4 |
| |
| MW: | 350.5 |
| |
| Source: | Synthetic. |
| |
| CAS: | 56985-40-1 |
| |
| Purity: | ≥98% (TLC) |
| |
| Identity: | Identity determined by 1H-NMR. |
| |
| Appearance: | Pale yellow oil. |
| |
| Solubility: | Soluble in DMF (100mg/ml), DMSO, 100% ethanol, DMSO, or PBS, pH 7.2 (2mg/ml). |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 years after receipt when stored at -20°C. We do not recommend storing aqueous solutions for more than one day. |
| |
| Technical Info/Product Notes: | Note: Product is not sterile. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Inhibition of neurogenic contractions in renal arteries and of cholinergic contractions in coronary arteries by the presumed inhibitor of ADP-ribosylation factor 6, NAV2729: R. Huang, et al.; Naunyn Schmiedebergs Arch. Pharmacol.
395, 471 (2022),
Abstract;
Bleeding diathesis in mice lacking JAK2 in platelets: N. Eaton, et al.; Blood Adv.
5, 2969 (2021),
Abstract;
Correlation of Pulse Wave Transit Time with Pulmonary Artery Pressure in a Porcine Model of Pulmonary Hypertension: F. Mueller-Graf, et al.; Biomedicines
9, 1212 (2021),
Abstract;
Genetic Labeling of Cells Allows Identification and Tracking of Transgenic Platelets in Mice: I. Krüger, et al.; Int. J. Mol. Sci.
22, 3710 (2021),
Abstract;
Full Text
Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction: A. Tamalunas, et al.; Life Sci.
281, 119771
(2021),
Abstract;
Loss of Hem1 disrupts macrophage function and impacts migration, phagocytosis, and integrin-mediated adhesion: S. Stahnke, et al.; Curr. Biol.
31, 2051 (2021),
Abstract;
Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension: L. Shen, et al.; Biochem. Pharmacol.
166, 242 (2019),
Abstract;
Simvastatin causes pulmonary artery relaxation by blocking smooth muscle ROCK and calcium channels: Evidence for an endothelium-independent mechanism: M. Absi, et al.; PLoS One
14, e0220473 (2019),
Abstract;
Full Text
Vitamin C Deficiency Reduces Muscarinic Receptor Coronary Artery Vasoconstriction and Plasma Tetrahydrobiopterin Concentration in Guinea Pigs: G.F. Skovsted, et al.; Nutrients
9, 691 (2017),
Application(s): Guinea Pig samples,
Abstract;
Full Text
Broad-range TRP channel inhibitors (2-APB, flufenamic acid, SKF-96365) affect differently contraction of resistance and conduit femoral arteries of rAT: M. Bencze, et al.; Eur. J. Pharmacol.
765, 533 (2015),
Application(s): Induced arterial contractions,
Abstract;
Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the pre-contractile agents: C. Benyahia, et al.; Prostaglandins Other Lipid Mediat.
121, 46 (2015),
Application(s): Evaluating the effects of PGI2 mimetics in rat pulmonary arteries,
Abstract;
Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation: N.S. Kirkby, et al.; FASEB. J.
29, 4568 (2015),
Abstract;
Full Text
αB-crystallin reduces ristocetin‑induced soluble CD40 ligand release in human platelets: Suppression of thromboxane A2 generation: M. Tsujimoto, et al.; Mol. Med. Rep.
12, 357 (2015),
Application(s): Platelet aggregation in human platelet-rich plasma,
Abstract;
Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries: P.P. Jain, et al.; Int. J. Nanomedicine
9, 3249 (2014),
Abstract;
Full Text
EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin: K.S. Sakariassen, et al.; Thromb. Res.
130, 746 (2012),
Abstract;
Mechanisms underlying increased reactivity of pulmonary arteries contralateral to a localized high-flow anastomosis: S. Pfister, et al.; J. Thorac. Cardiovasc. Surg.
141, 425 (2011),
Abstract;
Full Text
Salvianolic acid B and tanshinone IIA attenuate myocardial ischemia injury in mice by NO production through multiple pathways: C. Pan, et al.; Ther. Adv. Cardiovasc. Dis.
5, 99 (2011),
Abstract;
Secretoneurin facilitates endothelium-dependent relaxations in porcine coronary arteries: C.K. Chan, et al.; Am. J. Physiol. Heart Circ. Physiol.
300, H1159 (2011),
Abstract;
Full Text
Alterations in nitric oxide and endothelin-1 bioactivity underlie cerebrovascular dysfunction in ApoE-deficient mice: K. Yamashiro, et al.; J. Cereb. Blood. Flow Metab.
30, 1494 (2010),
Abstract;
Full Text
Calcium-independent phospholipase A(2) plays a key role in the endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat.: M.S. Wong, et al.; Am. J. Physiol. Heart Circ. Physiol.
298, H1260 (2010),
Abstract;
Full Text
Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue: J. Saklatvala, et al.; J. Biol. Chem.
271, 6586 (1996),
Abstract;
Full Text
Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements: P.M. Tymkewycz, et al.; Br. J. Pharmacol.
102, 607 (1991),
Abstract;
Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets: N. Liel, et al.; Prostaglandins
33, 789 (1987),
Abstract;
Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues: S.E. Burke, et al.; Br. J. Pharmacol.
78, 287 (1983),
Abstract;
Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations: R.A. Coleman, et al.; Br. J. Pharmacol.
73, 773 (1981),
Abstract;
Related Products
